LAS VEGAS – Topcon announced the launch of the Maestro2 Automated OCT/Fundus Camera with OCT angiography here at Vision Expo West.
Building on the 3D OCT-1 Maestro, the Maestro2 is a fully automated OCT system that can capture high-resolution, nonmydriatic, true color fundus photography, OCT and OCTA with the press of a button, the company said in a press release.
The Hood Report for analyzing the structure/function of glaucoma, a 360-degree rotating intuitive touchscreen and a small footprint are also new.
Topcon’s PinPoint Registration matches specified areas within the OCT and OCTA scans on the color fundus image, and Maestro2’s new follow-up scan feature scans the same location each patient visit, which can help the clinician track disease over time, the company stated.
A company representative noted that OCTA functionality is contingent on regulatory approval and is not currently available in all countries, including the U.S.
Genevieve Fay, vice president of global marketing for Topcon, also told Primary Care Optometry News that the company will be merging its software and medical divisions to form Topcon Health Care Solutions Jan. 1, 2020. She explained that with this restructuring, clinicians will be able to rent Topcon devices and purchase software subscriptions.
She also noted that a Myopia Module was to the Aladdin Biometer in early September, which will allow the clinician to measure axial length, among other parameters, and track changes over time.
In addition, Topcon is working in artificial intelligence in the areas of diabetic retinopathy and also detecting precursors to Alzheimer’s and Parkinson’s disease in the eye, Fay said.
“We’re excited to build software that will have even more effect on patients’ well-being so eye care professionals can become a bigger part of overall health,” she said. – by Nancy Hemphill, ELS, FAAO
Disclosure: Fay is employed by Topcon.
Editor's note: This story was updated to indicate that Maestro2's OCTA functionality is contingent on regulatory approval in some countries.